Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer

22Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence inter-val [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analy-ses suggest circulating tumor DNA may identify features of response and acquired resistance. SIGNIFICANCE: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer.

References Powered by Scopus

World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects

0
19952Citations
N/AReaders
Get full text

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial

2402Citations
N/AReaders
Get full text

The KRAS<sup>G12C</sup> inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients

875Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Colon Cancer, Version 3.2024

62Citations
N/AReaders
Get full text

Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistance

7Citations
N/AReaders
Get full text

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., … Kopetz, S. E. (2024). Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery, 14(6), 982–993. https://doi.org/10.1158/2159-8290.CD-24-0217

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

86%

Professor / Associate Prof. 1

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

38%

Biochemistry, Genetics and Molecular Bi... 3

38%

Agricultural and Biological Sciences 1

13%

Pharmacology, Toxicology and Pharmaceut... 1

13%

Article Metrics

Tooltip
Mentions
News Mentions: 16
Social Media
Shares, Likes & Comments: 35

Save time finding and organizing research with Mendeley

Sign up for free